Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
NCT06361238 on ClinicalTrials.gov · last registry update 2024-12-20
Recruiting now, toward 260 participants. Due to report 31 March 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: The incidence of delirium. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P3
- Drug
- liraglutideVictoza, Xultophy, Saxenda
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Sponsor type
- Other
- Enrollment
- 260
- Started
- 2024-11-19
- Primary completion
- 2027-03-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The incidence of delirium
Conditions studied
Delirium, Postoperative
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.